비호지킨림프종 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 질환 유형별, 약물 종류별, 투여 경로별, 유통 채널별, 지역별, 경쟁별(2020-2030년)
Non-Hodgkin Lymphoma Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type, By Drug Class, By Route of Administration, By Distribution Channel, By Region and Competition, 2020-2030F
상품코드:1881479
리서치사:TechSci Research
발행일:2025년 11월
페이지 정보:영문 187 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 비호지킨림프종 시장은 2024년에 72억 4,000만 달러로 평가되었으며, 2030년까지 CAGR 7.72%로 성장하여 113억 1,000만 달러에 달할 것으로 예측됩니다.
세계 비호지킨림프종 시장은 화학요법, 표적 치료제, CAR T 세포 치료와 같은 면역요법, 방사선 치료, 줄기세포 이식 등 다양한 림프종 아형에 대한 종합적인 진단 도구와 치료 개입으로 구성되어 있습니다. 시장 성장은 주로 비호지킨림프종 발생률의 증가와 표적 치료제 및 면역치료와 같은 첨단 치료법에 대한 선호도가 높아짐에 따라 주도되고 있습니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
72억 4,000만 달러
시장 규모 : 2030년
113억 1,000만 달러
CAGR : 2025-2030년
7.72%
가장 빠르게 성장하는 부문
T 세포 림프종
최대 시장
북미
주요 시장 촉진요인
세계 비호지킨림프종 시장은 치료 효과와 환자 예후를 개선하는 표적 치료 및 면역요법의 지속적인 발전으로 인해 크게 성장하고 있습니다. 림프종 병태생리에 관여하는 분자 경로를 표적으로 하는 새로운 약물의 지속적인 개발로, 특히 재발성 또는 난치성 질환을 가진 환자들을 위한 치료 옵션이 확대되고 있습니다.
주요 시장 과제
새로운 치료제, 특히 첨단 생물학적 제제 및 CAR T 세포 치료에 따른 막대한 비용은 세계 비호지킨림프종 시장 성장에 큰 장벽으로 작용하고 있습니다. 이러한 고비용은 특히 예산이 한정된 의료 시스템이나 보험 제도가 제대로 갖춰지지 않은 지역에서는 환자의 생명을 구할 수 있는 치료에 대한 접근성을 직접적으로 제한하고 있습니다.
주요 시장 동향
비호지킨림프종 시장은 주로 고급 유전체 프로파일링에 의해 주도되는 맞춤형 의료로의 급속한 전환에 의해 크게 영향을 받고 있습니다. 이러한 추세는 환자 개개인의 고유한 유전적 구성에 따라 치료법을 조정하는 데 중점을 두고 있으며, 이는 보다 표적화되고 효과적인 치료 개입으로 이어지고 있습니다.
The Global Non-Hodgkin Lymphoma Market, valued at USD 7.24 Billion in 2024, is projected to experience a CAGR of 7.72% to reach USD 11.31 Billion by 2030. The global Non-Hodgkin Lymphoma market comprises a comprehensive array of diagnostic tools and therapeutic interventions, including chemotherapy, targeted therapies, immunotherapies such as CAR T-cell therapy, radiation, and stem cell transplantation, tailored for various lymphoma subtypes. Market growth is primarily driven by the increasing global incidence of Non-Hodgkin Lymphoma and a rising preference for advanced treatment modalities like targeted therapies and immunotherapies.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 7.24 Billion
Market Size 2030
USD 11.31 Billion
CAGR 2025-2030
7.72%
Fastest Growing Segment
T-cell Lymphoma
Largest Market
North America
Key Market Drivers
The Global Non-Hodgkin Lymphoma market is significantly propelled by sustained advancements in targeted therapies and immunotherapies, which offer enhanced treatment efficacy and improved patient outcomes. The continuous development of novel agents specifically designed to target molecular pathways implicated in lymphoma pathogenesis has expanded therapeutic options, particularly for patients with relapsed or refractory disease. For instance, according to Genmab, on June 26, 2024, the FDA approved epcoritamab-bysp, known as EPKINLY(R), for relapsed or refractory follicular lymphoma, representing the first and only T-cell engaging bispecific antibody administered subcutaneously for this indication. This progress not only provides new lifelines for patients but also fuels market expansion through the introduction of premium-priced, innovative treatments.
Key Market Challenges
The substantial cost associated with novel therapeutics, particularly advanced biologics and CAR T-cell treatments, presents a significant impediment to the growth of the global Non-Hodgkin Lymphoma market. These high expenditures directly limit patient access to potentially life-saving interventions, especially in healthcare systems with constrained budgets or in regions lacking robust insurance frameworks.
Key Market Trends
The non-Hodgkin lymphoma market is significantly influenced by the accelerating shift towards personalized medicine, primarily propelled by advanced genomic profiling. This trend emphasizes tailoring treatments based on an individual patient's unique genetic makeup, leading to more targeted and effective therapeutic interventions. For instance, the European Hematology Association's (EHA) guidelines for large B-cell lymphomas and peripheral T-cell lymphomas in 2025 highlight the increasing cruciality of molecular profiling for accurate diagnosis and subtype identification, which directly informs personalized treatment strategies. The expedited delivery of such critical diagnostic information is further advanced, as exemplified by the FDA approval of Thermo Fisher Scientific's Oncomine Dx Express Test in September 2025, designed for companion diagnostics and tumor profiling with results available in as little as 24 hours. This capability enables faster and more precise treatment decisions, enhancing patient outcomes and driving market expansion for advanced diagnostic solutions.
Key Market Players
AbbVie Inc
Bristol-Myers Squibb Company
AstraZeneca plc
Johnson & Johnson Services, Inc.
Novartis AG
Seagen, Inc (Pfizer Inc.)
Bayer AG
F. Hoffmann-La Roche Ltd
Gilead Sciences Inc
Merck & Co. Inc
Report Scope:
In this report, the Global Non-Hodgkin Lymphoma Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Non-Hodgkin Lymphoma Market, By Disease Type:
B-cell Lymphomas
T-cell Lymphoma
Non-Hodgkin Lymphoma Market, By Drug Class:
Monoclonal Antibodies
Antibody-Drug Conjugates
BTK/BCL-2 Kinase Inhibitors
PI3 Kinase Inhibitors
Others
Non-Hodgkin Lymphoma Market, By Route of Administration:
Oral
Parenteral
Others
Non-Hodgkin Lymphoma Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Others
Non-Hodgkin Lymphoma Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the Global Non-Hodgkin Lymphoma Market.
Available Customizations:
Global Non-Hodgkin Lymphoma Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Non-Hodgkin Lymphoma Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Disease Type (B-cell Lymphomas, T-cell Lymphoma)
5.2.2. By Drug Class (Monoclonal Antibodies, Antibody-Drug Conjugates, BTK/BCL-2 Kinase Inhibitors, PI3 Kinase Inhibitors, Others)
5.2.3. By Route of Administration (Oral, Parenteral, Others)
5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others)
5.2.5. By Region
5.2.6. By Company (2024)
5.3. Market Map
6. North America Non-Hodgkin Lymphoma Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Disease Type
6.2.2. By Drug Class
6.2.3. By Route of Administration
6.2.4. By Distribution Channel
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Non-Hodgkin Lymphoma Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Disease Type
6.3.1.2.2. By Drug Class
6.3.1.2.3. By Route of Administration
6.3.1.2.4. By Distribution Channel
6.3.2. Canada Non-Hodgkin Lymphoma Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Disease Type
6.3.2.2.2. By Drug Class
6.3.2.2.3. By Route of Administration
6.3.2.2.4. By Distribution Channel
6.3.3. Mexico Non-Hodgkin Lymphoma Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Disease Type
6.3.3.2.2. By Drug Class
6.3.3.2.3. By Route of Administration
6.3.3.2.4. By Distribution Channel
7. Europe Non-Hodgkin Lymphoma Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Disease Type
7.2.2. By Drug Class
7.2.3. By Route of Administration
7.2.4. By Distribution Channel
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Non-Hodgkin Lymphoma Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Disease Type
7.3.1.2.2. By Drug Class
7.3.1.2.3. By Route of Administration
7.3.1.2.4. By Distribution Channel
7.3.2. France Non-Hodgkin Lymphoma Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Disease Type
7.3.2.2.2. By Drug Class
7.3.2.2.3. By Route of Administration
7.3.2.2.4. By Distribution Channel
7.3.3. United Kingdom Non-Hodgkin Lymphoma Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Disease Type
7.3.3.2.2. By Drug Class
7.3.3.2.3. By Route of Administration
7.3.3.2.4. By Distribution Channel
7.3.4. Italy Non-Hodgkin Lymphoma Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Disease Type
7.3.4.2.2. By Drug Class
7.3.4.2.3. By Route of Administration
7.3.4.2.4. By Distribution Channel
7.3.5. Spain Non-Hodgkin Lymphoma Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Disease Type
7.3.5.2.2. By Drug Class
7.3.5.2.3. By Route of Administration
7.3.5.2.4. By Distribution Channel
8. Asia Pacific Non-Hodgkin Lymphoma Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Disease Type
8.2.2. By Drug Class
8.2.3. By Route of Administration
8.2.4. By Distribution Channel
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Non-Hodgkin Lymphoma Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Disease Type
8.3.1.2.2. By Drug Class
8.3.1.2.3. By Route of Administration
8.3.1.2.4. By Distribution Channel
8.3.2. India Non-Hodgkin Lymphoma Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Disease Type
8.3.2.2.2. By Drug Class
8.3.2.2.3. By Route of Administration
8.3.2.2.4. By Distribution Channel
8.3.3. Japan Non-Hodgkin Lymphoma Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Disease Type
8.3.3.2.2. By Drug Class
8.3.3.2.3. By Route of Administration
8.3.3.2.4. By Distribution Channel
8.3.4. South Korea Non-Hodgkin Lymphoma Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Disease Type
8.3.4.2.2. By Drug Class
8.3.4.2.3. By Route of Administration
8.3.4.2.4. By Distribution Channel
8.3.5. Australia Non-Hodgkin Lymphoma Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Disease Type
8.3.5.2.2. By Drug Class
8.3.5.2.3. By Route of Administration
8.3.5.2.4. By Distribution Channel
9. Middle East & Africa Non-Hodgkin Lymphoma Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Disease Type
9.2.2. By Drug Class
9.2.3. By Route of Administration
9.2.4. By Distribution Channel
9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Non-Hodgkin Lymphoma Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Disease Type
9.3.1.2.2. By Drug Class
9.3.1.2.3. By Route of Administration
9.3.1.2.4. By Distribution Channel
9.3.2. UAE Non-Hodgkin Lymphoma Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Disease Type
9.3.2.2.2. By Drug Class
9.3.2.2.3. By Route of Administration
9.3.2.2.4. By Distribution Channel
9.3.3. South Africa Non-Hodgkin Lymphoma Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Disease Type
9.3.3.2.2. By Drug Class
9.3.3.2.3. By Route of Administration
9.3.3.2.4. By Distribution Channel
10. South America Non-Hodgkin Lymphoma Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Disease Type
10.2.2. By Drug Class
10.2.3. By Route of Administration
10.2.4. By Distribution Channel
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Non-Hodgkin Lymphoma Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Disease Type
10.3.1.2.2. By Drug Class
10.3.1.2.3. By Route of Administration
10.3.1.2.4. By Distribution Channel
10.3.2. Colombia Non-Hodgkin Lymphoma Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Disease Type
10.3.2.2.2. By Drug Class
10.3.2.2.3. By Route of Administration
10.3.2.2.4. By Distribution Channel
10.3.3. Argentina Non-Hodgkin Lymphoma Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Disease Type
10.3.3.2.2. By Drug Class
10.3.3.2.3. By Route of Administration
10.3.3.2.4. By Distribution Channel
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Non-Hodgkin Lymphoma Market: SWOT Analysis
